12:00 AM
Apr 29, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

BAY41-6551: Phase III started

Bayer started the double-blind, placebo-controlled, international Phase III INHALE 1 trial to evaluate 400 mg aerosolized BAY41-6551 given twice daily for 10 days in about 651 patients with Gram-negative pneumonia receiving standard of care IV...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >